Quick Summary
- Shares of UNH advanced 1.5% on Monday, reaching an intraday peak of $283.30 and settling at $281.46.
- CMS revealed a final Medicare Advantage payment rate increase of 2.48% for 2027, significantly exceeding the January preliminary figure of 0.09%.
- This improved rate will generate approximately $13 billion in extra government reimbursements for health insurers in the coming year.
- Prior to first-quarter results scheduled for April 21, Raymond James elevated UNH to “outperform” from “market perform” with a $330 target price.
- In premarket activity, Humana surged 11% on the Medicare announcement while both UNH and CVS Health climbed over 6%.
Shares of UNH commenced Monday’s session at $277.26, peaked at $283.30, and ended the day at $281.46 — representing a 1.5% increase.
UnitedHealth Group Incorporated, UNH
The equity has declined approximately 22% during the past half-year and currently trades beneath both its 50-day moving average of $283.03 and 200-day moving average of $319.62. Wall Street’s consensus price objective stands at $363.38.
Following the market close on Monday, the Centers for Medicare and Medicaid Services (CMS) unveiled its final payment rate structure for Medicare Advantage plans in 2027. The rate reflected a 2.48% average increase — a substantial improvement over the 0.09% preliminary figure disclosed in January that had shaken investor confidence in the healthcare insurance sector.
The January preliminary announcement had triggered selloffs in UNH and Humana when first revealed. Market participants were anxiously awaiting any upward revision in the final determination.
This enhanced rate structure equates to roughly $13 billion in incremental government funding for health insurers in the upcoming year. Following the disclosure, shares of UNH and CVS Health, which owns Aetna, jumped more than 6% during premarket hours. Humana experienced an even steeper climb of 11%.
Why Medicare Advantage Matters for Insurers
Medicare Advantage represents the private-sector option to conventional Medicare and currently provides coverage for approximately 35 million Americans this year, based on data from KFF, a health research organization. Participation has expanded consistently and now surpasses enrollment in traditional Medicare programs.
For major health insurers like UnitedHealth, Medicare Advantage serves as a critical income source. A nearly flat rate adjustment — in an environment where healthcare costs are increasing 7% to 9% annually — would have functioned as an effective reduction, according to the Better Medicare Alliance.
Mizuho analyst Jared Holz characterized the 2.48% final rate as “certainly better than the government’s initial rate decision,” noting it establishes conditions for potential margin growth in the coming year if insurers maintain their focus on benefit optimization and cost management.
TD Cowen’s Ryan Langston had anticipated a smaller adjustment between 1% and 1.5%, meaning the final announcement exceeded certain analyst projections.
Cross-party political pressure had complicated the rate outlook. Lawmakers from both major parties have expressed concern regarding insurers obtaining elevated reimbursements through diagnostic coding practices — commonly referred to as risk adjustment. The Biden administration initiated stricter enforcement of related regulations, and the Trump administration’s January preliminary proposal indicated ongoing regulatory oversight.
First-Quarter Results Expected April 21
On April 1, Raymond James raised its rating on UNH from “market perform” to “outperform,” establishing a $330 price objective. The investment firm pointed to the possibility of management demonstrating operational stability heading into the earnings announcement.
Barclays maintains an “overweight” stance with a $327 target. Mizuho and Leerink Partners similarly rate the stock “outperform,” with price targets of $350 and $345 respectively.
Among the 28 analysts tracking UNH, 18 recommend Buy, seven suggest Hold, and two advise Sell. MarketBeat’s aggregated rating is Moderate Buy.
First-quarter financial results are scheduled for April 21. During the fourth quarter, UNH reported adjusted earnings of $2.11 per share, surpassing the analyst consensus of $2.09. Total revenue reached $113.73 billion, reflecting year-over-year growth of 12.3%. Company guidance calls for full-year 2026 EPS of $17.75.
UNH distributes a quarterly dividend of $2.21 per share, equating to a 3.1% annualized yield at current price levels.
Institutional investors control 87.86% of outstanding shares, with recent stake increases from Norges Bank, Berkshire Hathaway, and T. Rowe Price.
